Guide pédagogique à l’intention des femmes enceintes et des mères vivant avec le VIH
Santé positive, dignité et prévention pour les femmes et leurs bébés a été conçu pour être utilisé par des réseaux de femmes vivant avec le VIH, des groupes de femmes, des pairs-éducateu...rs ou d’autres personnes souhaitant aider les femmes vivant avec le VIH à prendre certaines décisions importantes avant, pendant, et après leur grossesse. Il ne remplace pas la visite à un établissement de santé ni la consultation d’un professionnel de santé.
Ils apportent des informations précises et complètes qui permettront aux femmes enceintes et aux mères vivant avec le VIH de connaître leurs droits et ainsi de prendre des décisions éclairées concernant leur santé et la santé de leur bébé.
more
Health and Human Rights Journal
December 2016 / Volume 18 / Number 2 / Papers, 171-182
Human Rights, Minimum Standards and Monitoring at the European and International Levels
Compendium of Case Studies
DHS Working Papers No. 85
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on
dolutegravir-based antiretroviral therapy (November 2020– September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 ...(30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.
more
Topics in Antiviral Medicine 25 Issue 2 May/June 2017
Epidemiologisches Bulletin; 1. Dezember 2014 / Nr. 48
Toolkit
HIV Treatment and Care
A GUIDE FOR HEALTH CARE PROVIDERS.
This material was reprinted, with permission, from the National Sexual Violence Resource Center’s publication entitled Assessing
patients for sexual violence: A guide for health care providers. This guide is available by visiting www.nsvrc.org
Dispatches
DOI: http://dx.doi.org/10.3201/eid2203.151607
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 3, March 2016
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN...) as an additional HIV prevention choice, as part of combination HIV prevention approaches. LEN, administered twice a year as PrEP, has been shown to be highly effective at reducing the risk of HIV acquisition. In this guideline, WHO also recommends using HIV rapid diagnostic tests (RDTs) for individuals initiating or continuing long-acting injectable PrEP, such as LEN and long acting injectable cabotegravir (CAB-LA). Flexible HIV testing approaches are essential for ensuring that testing does not become a barrier to accessing or continuing PrEP, including long-acting injectable options.
more